Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by
R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with
zanubrutinib for newly-diagnosed Mantle Cell Lymphoma (MCL).